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D8
+ T cells and NK cells are major cytotoxic effector cells of the immune system responsible for the destruction of pathogen-infected cells and cancer cells 1, 2 . CD8
+ T cells detect specific antigens via the T cell antigen receptor (TCR), whereas NK cells are innate lymphocytes that use different receptors for sensing target cells. These effector cells also function in different phases of an immune response, with NK cells acting in the early phase of innate immunity and CD8 + T cells acting in the late phase of adaptive immunity. NK cells also play an important role in regulating T cell responses 3 . Thus, CD8
+ T cells and NK cells are considered complementary cytotoxic effectors and have been actively explored for cancer immunotherapy 4 . A common feature of CD8 + T cells and NK cells is their dependence on the cytokine IL-15 for homeostasis 5, 6 . IL-15 is a member of the common γ-chain (γ c ) family of cytokines that function through the IL-15 receptor (IL-15R) complex, composed of IL-15Rα, IL-15Rβ (also called IL-2Rβ or CD122) and γ c (also called CD132). IL-15 induces signaling via a transpresentation mechanism, in which IL-15Rα binds to IL-15 and transpresents IL-15 to the IL-15R β-γ c complex on responding cells 6 . Under physiological conditions, IL-15 is specifically required for the homeostasis of CD8 + T cells and NK cells that express high levels of IL-15R β-γ c heterodimer 7, 8 . Exogenously administered IL-15 can also promote activation of CD8 + T cells and NK cells and has therefore been exploited as an adjuvant for cancer immunotherapies [9] [10] [11] . However, the physiological function of IL-15 in regulating the activation of CD8 + T cells and NK cells is poorly defined and how signal transduction from IL-15R is regulated is also unknown.
Ubiquitination is a crucial mechanism that regulates diverse biological processes, including immune responses 12 . Ubiquitination is a reversible reaction counter-regulated by ubiquitinating enzymes and deubiquitinases (DUBs) 13 . In vitro studies identified an atypical DUB, Otub1, which can both directly cleave ubiquitin chains from target proteins and indirectly inhibit ubiquitination by blocking the function of specific ubiquitin-conjugating enzymes (E2s), including the K63-specific E2 Ubc13 (refs. [14] [15] [16] [17] ). However, the in vivo physiological function of Otub1 has been poorly defined. In the present study, we identified Otub1 as a pivotal regulator of IL-15R signaling and homeostasis of CD8 + T cells and NK cells. Otub1 controls IL-15-stimulated activation of AKT, a pivotal kinase for T cell activation, metabolism and effector functions [18] [19] [20] . Our results suggest that Otub1 also controls the activation and function of CD8 + T cells and NK cells in immune responses against infections and cancer.
Results
T cell-specific Otub1 deficiency causes aberrant activation of CD8
+ T cells. To study the function of Otub1 in T cells, we generated mice with conditional knockout of Otub1 in T cells (TKO mice; Supplementary Fig. 1a-c) . The Otub1-TKO mice had normal frequencies of thymocyte and peripheral T cell populations ( Supplementary Fig. 1d ,e). However, they had increased frequencies of effector/memory-like (CD44 hi ) CD8
+ T cells producing the effector cytokines interferon (IFN)-γ, tumor necrosis factor (TNF) and IL-2 (Fig. 1a,b) . Although Otub1 was similarly expressed in CD4
+ and CD8 + T cells (data not shown), Otub1 deficiency did not increase the frequency of CD4 + effector/memory T cells (Fig. 1a,c) . The Otub1-TKO and wild-type (WT) mice had similar frequencies of regulatory T (T reg ) cells and the Otub1-deficient T reg cells were fully functional in suppressing naive CD4 + T cells ( Supplementary Fig. 2a-c) . Mixed-bone marrow adoptive transfer
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studies revealed that Otub1-TKO CD8 + T cells had higher frequencies of the effector/memory-like population than WT CD8 + T cells, even in the same recipient mice ( Supplementary Fig. 2d ,e), suggesting a cell-intrinsic role for Otub1 in maintaining CD8
+ T cell homeostasis. Furthermore, Otub1-deficient naive CD8
+ T cells were hyper-responsive to in vitro activation (Fig. 1d) . Similar results were obtained with naive CD8
+ T cells from OT-I mice, which produce CD8 + T cells with a recombinant TCR specific for the chicken ovalbumin (OVA) peptide SIINFEKL 21 ( Fig. 1e) . By contrast, Otub1 deficiency had no effect on naive CD4 + T cell activation (Fig. 1d) . To examine the in vivo function of Otub1, we used a bacterial infection model employing a recombinant Listeria monocytogenes strain expressing chicken ovalbumin, LM-OVA. The Otub1-TKO mice displayed markedly enhanced immune responses against LM-OVA infection, as demonstrated by reduced liver bacterial load and increased frequencies of antigen-specific CD8
+ effector T cells producing IFN-γ (Fig. 1f,g ). Similar results were obtained using WT and Otub1-TKO OT-I mice producing OVA-specific CD8 + T cells (Fig. 1h) . These results suggest that Otub1 maintains CD8 + T cell homeostasis and negatively regulates CD8 + T cell activation.
Otub1 regulates CD8
+ T cell responses to IL-15. The γ c family cytokines IL-7 and IL-15 are important for T cell homeostasis 5, 22 . While IL-7 regulates both CD4 + and CD8 + T cells, IL-15 is particularly important for regulating CD8 + T cells that express high levels of IL-15Rβ and γ c (refs. 7, 8 ). Because Otub1 deficiency had a selective effect on CD8 + T cells ( Fig. 1a) , we tested whether Otub1 played a role in regulating CD8
+ T cell responses to IL-15 by performing mixed-CD8 + T cell transfer using Il15ra +/+ or Il15ra −/− recipient mice (Fig. 2a) . Because IL-15Rα is required for IL-15 transpresentation, T cells transferred to Il15ra −/− mice are defective in IL-15 stimulation 23, 24 . In the Il15ra +/+ recipients, Otub1-TKO CD8 + T cells had much higher frequencies of memory-like T cells than WT CD8 + T cells (Fig. 2b,c) . However, this phenotype was no longer significant IL-2 (ng ml ) and anti-CD28 (1 μg ml
−1
). f-h, Liver bacteria titer (f) and flow cytometry analysis of the frequency of IFN-γ-producing CD8 + effector T cells in OVA 257-264 -stimulated splenic T cells (g,h) derived from WT and Otub1-TKO mice (g; WT, n = 6; TKO, n = 4) or WT OT-I and TKO OT-I mice (h; WT OT-I, n = 6; TKO OT-I, n = 5) infected with LM-OVA for 7 d. Data summarize three (b-h) or five (a) independent experiments. Summary graphs are presented as mean ± s.e.m. with P values determined by two-tailed Student's t test. *P < 0.05, **P < 0.01, ***P < 0.0001. Numbers in quadrants indicate percentages of cells.
in Il15ra -/-recipients, suggesting a role for Otub1 in controlling CD8 + T cell responses to IL-15 ( Fig. 2b,c) . We also examined the effect of Otub1 deficiency on IL-15-mediated CD8 + T cell proliferation under lymphopenic conditions. For this, we used OT-I CD8 + T cells: because the OT-I TCR does not respond to commensal antigens, OT-I T cell expansion is mediated by homeostatic cytokines, predominantly IL-7 and IL-15 (refs. 5, 25 ). WT OT-I T cells proliferated to a similar extent in Il15ra +/+ and Il15ra −/− recipient mice (Fig. 2d) , consistent with the involvement of both IL-7 and IL-15 in mediating lymphopenic T cell proliferation 5, 7, 25 . However, the hyperproliferation of Otub1-TKO OT-I T cells was critically dependent on IL-15, as it was largely Relative expression indicates the change in target gene expression in a given sample relative to expression of the housekeeping gene Actb in the same sample. Data are from one experiment (g) or three independent experiments (b-f, h). Summary data are shown as mean ± s.e.m. with P values determined by two-tailed Student's t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
eliminated in the Il15ra
−/− recipient mice (Fig. 2d) Fig. 3a) . Furthermore, in a T cell adoptive transfer experiment, Otub1-TKO OT-I CD8 + T cells isolated from Il15ra +/+ recipients, but not Il15ra
recipients, displayed the hyperactivation phenotype (Fig. 2e) . As an in vivo model, we performed LM-OVA infection using Il15ra
or Il15ra −/− mice adoptively transferred with a mixture of WT and Otub1-TKO naive OT-I CD8 + T cells ( Supplementary Fig. 3b,c) . In Il15ra +/+ recipients, Otub1-TKO OT-I T cells displayed a much stronger response to LM-OVA infection than WT OT-I T cells, but this phenotype was not detected in the Il15ra −/− recipients ( Fig. 2f and Supplementary Fig. 3d ). Thus, Otub1 controls IL-15-mediated priming of CD8 + T cells for antigen-specific responses both in vitro and in vivo.
RNA sequencing revealed that Otub1-TKO naive OT-I T cells had upregulated expression of a large number of genes under homeostatic conditions ( Supplementary Fig. 3e ), including signatures associated with effector/memory functions and stem cell memory T (T SCM ) cells (Fig. 2g) 28 . To study the function of Otub1 in NK cell regulation, we inducibly deleted Otub1 in adult mice using a tamoxifen-inducible Cre (CreER) system (Fig. 3a,b) . As expected from the Otub1-TKO result (Fig. 1a) , mice with induced knockout of Otub1 (Otub1-iKO mice) had increased frequencies of memory-like CD8 + T cells (Fig. 3c) . Importantly, although Otub1 deletion had no effect on total NK cell numbers in the spleen, it markedly increased the frequency of stage 4 mature NK cells (CD11b (Fig. 3d,e) . Consistent with this, Otub1-iKO NK cells were hyper-responsive to cytokine-stimulated activation, detected on the basis of production of granzyme B and the chemokine CCL5 ( Fig. 3f-h ), which mediate NK cell effector function and recruitment of type 1 conventional dendritic cells (cDC1s), respectively 29 . These results suggest that Otub1 controls the maturation and activation of NK cells, further emphasizing the role of this DUB in regulating IL-15 responses.
Otub1 regulates the AKT axis of IL-15 receptor signaling.
Stimulation of naive CD8
+ T cells with IL-15 triggered activation of the transcription factor Stat5 and the kinase AKT, as shown by their site-specific phosphorylation (Fig. 4a ). Otub1 deficiency did not affect Stat5 activation but enhanced activation of AKT (Fig. 4a) . AKT activation is mediated by phosphorylation at T308 and S473. Phosphorylation of AKT at T308 is crucial for activation of the metabolic kinase mTORC1, whereas phosphorylation of AKT at S473 is required for phosphorylating and inactivating the FOXO family of transcription factors, which promote CD8 + T cell effector functions 30, 31 . Otub1 deficiency enhanced IL-15-stimulated phosphorylation of AKT at S473 as well as Foxo1 and Foxo3 ( Fig. 4a and Supplementary Fig. 4a ). IL-15-stimulated phosphorylation of AKT at T308 was relatively weak, which required loading more cell lysates for clear detection ( Supplementary Fig. 4a ). Nevertheless, phosphorylation of AKT at T308 was also enhanced in Otub1-deficient CD8 + T cells ( Supplementary Fig. 4a ). Otub1 deficiency only had a weak effect on IL-2-and IL-7-stimulated phosphorylation of AKT ( Supplementary Fig. 4b ). Notably, the receptors of IL-2 and IL-15 have two common subunits, IL-2/IL-15Rβ and γ c , although these two cytokines display different biological functions 32 . Our finding also suggested signaling differences between these two closely related cytokines. The role of Otub1 in regulating IL-15-stimulated AKT activation was further demonstrated using an IL-15-responsive T cell line, 15R-KIT (human KIT-225 cell line stably transfected with IL-15Rα). OTUB1 knockdown in 15R-KIT T cells strongly promoted IL-15-stimulated AKT phosphorylation (Fig. 4b) . Furthermore, Otub1 deficiency in NK cells also enhanced IL-15-stimulated activation of AKT, but not activation of Stat5 (Fig. 4c) . Thus, Otub1 controls the AKT axis of IL-15R signaling in both CD8
+ T cells and NK cells. Because Otub1-deficient CD8 + T cells were hyper-responsive to TCR-CD28 stimulation in vitro and antigen-specific responses in vivo ( Fig. 1d-h ), we examined the effect of Otub1 deletion on TCR signaling. Otub1 deficiency did not influence phosphorylation of the protein tyrosine kinase Zap70, the adaptor protein SLP76 or the MAP kinase ERK ( Supplementary Fig. 4c ). However, Otub1 deficiency markedly enhanced TCR-CD28-stimulated activation of AKT and phosphorylation of several AKT downstream proteins, including the transcription factors Foxo1 and Foxo3 and the mTORC1 targets S6 kinase (S6K), ribosomal S6 protein and 4E-BP1 (Fig. 4d) . On the other hand, Otub1 deficiency did not affect TCR-CD28-stimulated AKT signaling in CD4 + T cells ( Supplementary  Fig. 4d ), consistent with the finding that Otub1 controlled the activation of CD8
+ , but not CD4 + , T cells ( Fig. 1d ). To examine whether the TCR-CD28-stimulated AKT hyperactivation in Otub1-deficient CD8 + T cells was due to IL-15 priming, we adoptively transferred WT or Otub1-TKO naive OT-I T cells to Il15ra +/+ or Il15ra −/− recipient mice and sorted the transferred T cells for AKT activation assays (Fig. 4e) . Otub1-TKO OT-I CD8 + T cells isolated from Il15ra
, recipient mice displayed hyperactivation of AKT (Fig. 4f) , suggesting that IL-15 primes CD8 + T cells for the AKT axis of TCR-CD28 signaling under the control of Otub1. In an effort to further explore the mechanism by which Otub1 selectively regulates AKT signaling in CD8 + T cells, we found that CD8 + , but not CD4 + , T cells contained abundant membraneassociated Otub1 (Fig. 4g) . Similarly to CD8 + T cells, NK cells also contained a high level of membrane-associated Otub1 (Fig. 4g) . The membrane association of Otub1 was not affected by TCR-CD28 signaling ( Fig. 4h ) but was critically dependent on IL-15, as it was diminished in CD8 + T cells derived from an IL-15-Rα-deficient host in a T cell transfer study (Fig. 4i,j) . Antibody-mediated IL-15 neutralization in WT OT-I mice also inhibited Otub1 membrane localization in CD8 + T cells ( Fig. 4k) . Because AKT activation occurs in various membrane compartments 33 , these findings provide insight into the mechanism underlying the function of Otub1 in the regulation of AKT.
Otub1 inhibits K63 ubiquitination and PIP 3 binding by AKT.
A key step in the activation of AKT is its recruitment to membrane compartments via interaction of its pleckstrin homology (PH) domain with the membrane lipid phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ) (ref. 34 ). Once in the membrane, AKT is phosphorylated at T308 and S473 by PDK1 and mTORC2, respectively. We found that IL-15 stimulated membrane translocation of AKT, which was greatly enhanced by OTUB1 knockdown (Fig. 5a ). OTUB1 knockdown had no obvious effect on the activity of AKT upstream regulators phosphatidylinositol-3-OH kinase (PI(3)K) and phosphatase and tensin homolog (PTEN) (data not shown), which catalyze the forward and reverse reactions that generate PIP 3 , respectively 35 . Interestingly, AKT was physically associated with OTUB1 in 15R-KIT cells and the association was strongly enhanced upon IL-15 stimulation (Fig. 5b) . In primary OT-I CD8 + T cells, the AKT-Otub1 interaction was barely detectable at steady state but was strongly induced by IL-15 ( Fig. 5c ). Otub1-AKT binding was also readily detected under transfection conditions ( Supplementary Fig. 4e ).
Because Otub1 is a DUB, we next examined whether Otub1 regulated the ubiquitination of AKT. IL-15 stimulated ubiquitination of AKT, which was enhanced upon OTUB1 knockdown (Fig. 5d,e) . Conversely, OTUB1 overexpression inhibited AKT ubiquitination, which was efficient for K63-linked, but not K48-linked, polyubiquitin chains (Fig. 5f) . A previous study identified three catalytic residues of Otub1: C91, D88 and H265 (ref. 36 ). We found that substitution of C91 only moderately inhibited the function of OTUB1 (data not shown), but simultaneous alteration of D88 and C91 generated an OTUB1 mutant that was unable to inhibit AKT ubiquitination (Fig. 5f ). WT Otub1, but not the D88A/C91S mutant, was also able to suppress AKT activation in reconstituted Otub1-deficient CD8
+ T cells and OTUB1 knockdown 15R-KIT cells ( Supplementary Fig. 4f,g ), thus suggesting that Otub1-mediated inhibition of AKT K63 ubiquitination contributes to the negative regulation of AKT activation.
TRAF6 is known to mediate growth-factor-induced AKT ubiquitination at K8 and K14 in cancer cells 37 . We found that alteration ) for the indicated time periods. The CCL5 results are presented as a histogram (g) and a dot plot (h). MFI, mean fluorescence intensity. Data summarize two (b-e) or three (f-h) independent experiments. Summary data are shown as mean ± s.e.m. with P values determined by two-tailed Student's t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
of K14 also abolished AKT ubiquitination under basal and IL-15-stimulation conditions (Fig. 5g,h ). However, alteration of K8 had no effect on AKT ubiquitination (Fig. 5g,h ). Consistent with this, alteration of K14, but not K8, abolished AKT phosphorylation (Fig. 5i) , suggesting that ubiquitination of AKT at K14 mediates activation by IL-15. To further assess the function of AKT K63 ubiquitination, we fused a K63 ubiquitin mutant (UbK63) to AKT or AKT K14R at the N terminus close to residue K14 (Fig. 5j) . The UbK63-AKT fusion protein behaved like AKT in responding to IL-15 for phosphorylation (Fig. 5k) . Fusion of UbK63 to AKT K14R largely rescued its defect in IL-15-stimulated phosphorylation as well as in ubiquitination (Fig. 5k,l) , suggesting that the fused UbK63 could serve as an acceptor ubiquitin for polyubiquitin chain formation and, thus, AKT activation.
AKT normally exists in a closed conformation owing to the intramolecular interaction between its N-terminal PH domain and C-terminal kinase domain 38 . Because ubiquitination often causes conformational changes, we surmised that ubiquitination of AKT might promote its PIP 3 -binding activity. While WT AKT and AKT K8R displayed strong PIP 3 -binding activity, the AKT K14R mutant was defective in PIP 3 binding (Fig. 5m) . Moreover, OTUB1 strongly inhibited the PIP 3 -binding activity of WT AKT and AKT K8R, but it did not affect the residual PIP 3 -binding activity of the K14R mutant (Fig. 5m) . Fusion of UbK63 to AKT(K14R), which restored its ubiquitination (Fig. 5l) , completely restored PIP 3 -binding function (Fig. 5n) . These results suggest that Otub1 deubiquitinates AKT to interfere with the PIP 3 binding and membrane translocation of AKT, thereby inhibiting its phosphorylation and activation.
Otub1 regulates important gene signatures and metabolic programing in activated CD8
+ T cells. RNA sequencing analysis of in vitro-activated CD8 + T cells revealed that Otub1-deficient CD8 + T cells had 1,254 significantly upregulated and 297 significantly downregulated genes as compared to WT CD8 + T cells ( Supplementary Fig. 5 ). The upregulated genes included those involved in activation and effector function or survival of CD8 T cells (Fig. 6a) . The major downregulated genes included those encoding the pro-apoptotic factor Bim and immune checkpoint molecules (Pd1, Vista and CD160) (Fig. 6a) . The most striking result was the upregulated expression of a metabolic gene signature in Otub1-deficient CD8 + T cells, particularly those involved in the glycolytic pathway, such as glucose transporter 1 (Glut1, also called Slc2a1) and hexokinase 2 (Hk2) (Fig. 6a and Supplementary Fig. 5 ). Immunoblot analyses confirmed the drastic upregulation of HK2, an enzyme catalyzing the first step of the glycolytic pathway 39 , in Otub1-TKO CD8 + T cells (Fig. 6b) . These findings are intriguing, as metabolic reprograming is a hallmark of T cell activation and is required for the function of effector T cells [40] [41] [42] .
We next performed Seahorse extracellular flux analyses to measure the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR), indicators of aerobic glycolysis and oxidative phosphorylation, respectively 40 . As compared to WT CD8 + T cells, Otub1-deficient CD8 + T cells had enhanced ECAR and maximum glycolytic capacity (stressed ECAR) under activated conditions (Fig. 6c,d ). Unlike glycolysis, OCR was not significantly altered by Otub1 deficiency (Fig. 6e,f) . Otub1 appeared to regulate glycolysis through controlling AKT, as a selective AKT inhibitor (AKTi) erased the ECAR differences between WT and Otub1-TKO CD8 + T cells (Fig. 6g,h) . The AKT inhibitor also blocked TCR-CD28-stimulated hyperexpression of the glycolysis-regulatory genes Glut1 and Hk2 and cytokine production in Otub1-TKO CD8 + T cells (Fig. 6i,j) . These results suggest that Otub1 controls glycolysis induction in activated CD8 + T cells via a mechanism that involves regulation of AKT signaling.
Otub1 deficiency impairs CD8
+ T cell self-tolerance. IL-15 is known to reduce the threshold of T cell activation and sensitizes CD8 + T cells for response to self-antigens 10, 43 . We examined the role of Otub1 in regulating CD8 + T cell self-tolerance using a well-defined mouse model, Pmel1, which produces CD8 + T cells with a transgenic TCR specific for the melanocyte self-antigen gp100 (ref. 44 ).
Pmel1 CD8
+ T cells are normally tolerant to the self-antigen gp100 and impaired self-tolerance causes the skin autoimmune condition vitiligo, which is characterized by hair depigmentation 44, 45 . Although WT Pmel1 mice only developed minor vitiligo when examined up to 9 months of age, 100% of the Otub1-TKO Pmel1 mice developed severe vitiligo, starting from around 3 months of age and becoming more severe over time (Fig. 7a and data not shown) . While WT Pmel1 CD8 + T cells were predominantly in a naive state, a large proportion of Otub1-TKO Pmel1 CD8 + T cells were activated, displaying CD44 and CXCR3 activation markers (Fig. 7b,c) . Furthermore, Otub1-TKO, but not WT, Pmel1 T cells responded to in vitro restimulation with the antigen gp100 by producing IFN-γ (Fig. 7d) . These results suggest that Otub1 controls CD8
+ T cell responses to microbial antigens and self-antigens in vivo.
Otub1 regulates anticancer immunity via both T cells and NK cells.
Although tolerance prevents autoimmunity, it poses a major obstacle to immune responses against cancer and a general principle of cancer immunotherapy is to overcome immune tolerance 46 .
Our finding that Otub1 controls the activation of CD8
+ T cells and NK cells, which are central components for cancer immunity 1, 2 , suggested a role for Otub1 in regulating antitumor immunity. We first tested the T cell-specific function of Otub1 by employing the Otub1-TKO mice and the murine melanoma model B16-OVA (in which B16 cells express the surrogate antigen ovalbumin). In comparison to WT mice, Otub1-TKO mice had significantly reduced tumor burden (Fig. 8a,b) coupled with increased frequencies of CD8 + effector T cells producing IFN-γ and granzyme B in both tumors and draining lymph nodes (Fig. 8c) . Furthermore, Otub1-TKO CD8 + T cells expressed higher levels of Glut1 than WT CD8 + T cells in the tumor microenvironment (Fig. 8d) , consistent with the role of Otub1 in regulating glycolysis (Fig. 6c,d ).
To examine the therapeutic potential of targeting Otub1, we employed a mouse model of adoptive T cell therapy 47 . We inoculated B6 mice with B16F10 melanoma cells and then treated the tumorbearing mice by adoptive transfer of in vitro-expanded CD8 + T cells derived from WT or Otub1-TKO Pmel1 mice (Fig. 8e) . Pmel1 CD8 + T cells recognize the tumor antigen gp100 expressed by B16F10 tumors. In comparison to the WT Pmel1 CD8
+ T cells, Otub1-TKO Pmel1 CD8
+ T cells were profoundly more effective in suppressing + T cells that were either not treated or stimulated with anti-CD3 and anti-CD28 in the presence of AKTi (3 μM) or solvent control DMSO for the indicated time periods (i) or for 66 h (j). Data are from one experiment (a) or summarize three independent experiments (b-j). Summary data are shown as mean ± s.e.m. with P values determined by two-tailed Student's t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
tumor growth and improving survival of the B16 tumor-bearing mice (Fig. 8f,g ).
We next employed the Otub1-iKO model, in which Otub1 is inducibly deleted in adult mice in different cell types and challenged mice with B16F10 tumor cells (Fig. 8h) . The Otub1-iKO mice had greatly reduced tumor burden as compared to WT mice (Fig. 8i,j) associated with increased number of tumor-infiltrating CD8 +
T cells and NK cells as well as CD4
+ T cells and cDC1 cells (Fig. 8k) . Moreover, tumor-infiltrating CD8 + T cells in the Otub1-iKO mice had a significantly higher frequency of effector cells expressing IFN-γ and granzyme B (Fig. 8l) . Similar results were obtained with the MC38 colon cancer model ( Supplementary Fig. 6a-c) . Antibody-mediated depletion of either CD8 + T cells or NK cells impaired the potent anticancer immunity of Otub1-iKO mice, causing an increase in tumor burden to a level similar to or higher than that in WT mice (Fig. 8m,n and Supplementary Fig. 6d,e) . NK cell depletion in Otub1-iKO mice drastically reduced the frequency of tumor-infiltrating cDC1 and CD4 + T cells, whereas CD8 + T cell depletion partially reduced the frequency of tumor-infiltrating cDC1 cells, but not CD4 + T cells (Fig. 8o) . These results suggest that hyperactivation of CD8 + T cells and NK cells contributes to the strong anticancer immunity in Otub1-iKO mice.
To assess the role of OTUB1 in regulating antitumor immunity in human cancers, we analyzed cancer databases for potential correlation of OTUB1 expression with a T cell gene signature in tumors. Interestingly, our analysis of human skin cutaneous melanoma databases revealed a remarkable inverse correlation between OTUB1 expression levels and the abundance of the CD8 + effector T cell gene signature as well as between OTUB1 expression levels and patient survival ( Supplementary Fig. 7) . Collectively, these results establish OTUB1 as an important regulator of antitumor immunity and implicate Otub1 as a potential target for cancer immunotherapy.
Discussion
The results presented here suggest a ubiquitin-dependent mechanism that regulates IL-15R signaling and the IL-15-dependent homeostasis of CD8 + T cells and NK cells and establish the DUB Otub1 as a crucial regulator. Otub1 controls IL-15-stimulated ubiquitination and activation of AKT, a kinase that mediates the activation and metabolic reprograming of CD8 + T cells. Despite the abundant expression of Otub1 in CD4 + T cells, Otub1 deficiency had no effect on the homeostasis of CD4 + T cells. This cell-typespecific function of Otub1 is explained by its role in regulating IL-15R signaling, which is specifically required for the homeostasis of CD8 + T cells and NK cells 7, 8, 26 . Our data suggest that homeostatic exposure of CD8 + T cells to IL-15 serves as a crucial priming step for antigen-specific CD8 + T cell activation, which is controlled by Otub1. T cell-specific deletion of Otub1 rendered CD8 + T cells hyper-responsive to bacterial infections in vivo and to activation by TCR-CD28 signals in vitro. This phenotype was due to aberrant priming of the naive CD8 + T cells by IL-15, as it was not detected in IL-15Rα-deficient mice. In CD8 + T cells and NK cells, Otub1 localizes to the membrane compartment. The membrane localization of Otub1 was dependent on IL-15 signaling, thus implicating Otub1 as a checkpoint of IL-15-mediated CD8 + T cell priming. Because AKT activation occurs in various membrane compartments 33 , these findings suggest that the membrane localization of Otub1 may facilitate its role in regulating AKT activation.
Otub1 regulates different aspects of CD8 + T cell activation and function. Otub1 deficiency sensitized CD8 + T cells for activation by both TCR-CD28 stimuli and Listeria infections and also promoted generation of antigen-specific effector cells. The crucial role of Otub1 in regulating CD8 + T cell responses was also revealed by the development of vitiligo in Otub1-TKO Pmel1 mice, which was caused by aberrant CD8 + T cell activation by the melanocyte self-antigen gp100. Another important function of Otub1 was to regulate the metabolic reprograming of activated CD8 + T cells, an essential mechanism for supporting proliferation and the generation and function of effector cells 40 . This function of Otub1 is in line with its role in AKT regulation, as AKT is a master kinase mediating the activation, metabolism and effector functions of CD8 + T cells [18] [19] [20] . 
T cells and cDC1 cells. Depletion of either NK cells or CD8
+ T cells impaired the anticancer immunity, erasing the differences between the WT and Otub1-iKO mice in tumor rejection. Antibodymediated cell-depletion studies revealed a crucial role for NK cells in mediating the recruitment of CD4 + T cells and cDC1 cells in the Otub1-iKO mice. In a model of adoptive T cell therapy, Otub1 deletion also enhanced the tumor-rejection activity of CD8 + effector T cells, which was consistent with the role of Otub1 in regulating the metabolism and expression of effector molecules of activated CD8 + T cells. These findings implicate Otub1 as a potential drug target for cancer immunotherapy.
The role of ubiquitination in regulating IL-15R signaling has been poorly defined. Our present study demonstrated Otub1 as a DUB specifically regulating the AKT axis of IL-15R signaling. A central step in AKT activation is its recruitment to the plasma membrane, where it is activated via S473 phosphorylation by mTORC2 and T308 phosphorylation by PDK1 (ref. 48 ). The membrane recruitment of AKT involves it binding, via N-terminal PH domain, to the membrane phospholipid PIP 3 . Our data suggest that Otub1-mediated AKT deubiquitination attenuates binding to PIP 3 . Notably, the K14 ubiquitination site of AKT is located in its PH domain. It is thought that inactive AKT exists in a closed conformation owing to intramolecular interaction between its N-terminal PH domain and C-terminal kinase domain 38 . We propose that ubiquitination of AKT in its PH domain may interfere with the intramolecular interaction, thereby facilitating exposure of the PH domain for PIP 3 binding.
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Flow cytometry analysis and cell sorting. Single-cell suspensions of splenocytes and lymph-node cells were subjected to flow cytometry analysis and cell sorting as previously described 50 using FACS Fortessa and FACSAria (BD Biosciences). For intracellular cytokine staining assays, T cells isolated from spleen, draining lymph nodes or tumors of mice or from in vitro cultures were stimulated for 4 h with PMA (50 ng ml −1 ) and ionomycin (500 ng ml −1 ) in the presence of monensin (10 μg ml −1 ) during the last hour. The stimulated cells were fixed in 2% paraformaldehyde and permeablized in 0.5% saponin and then subjected to cytokine staining and flow cytometry analyses. FACS data were analyzed in FlowJo v.9.7.7 and the proliferation index of cells labeled with carboxyfluorescein succinimidyl ester (CFSE) was calculated in FlowJo v.10 proliferation-modeling module. Gating strategies are summarized in Supplementary Fig. 8. L. monocytogenes infection. Age-and sex-matched WT and knockout mice (6-8 weeks old) were infected intravenously with 1 × 10 5 colony-forming units (CFU) of OVA-expressing recombinant L. monocytogenes (LM-OVA) 51 (provided by H. Shen, University of Pennsylvania). Seven days after infection, the mice were killed to allow analysis of OVA-specific CD8
+ effector T cells in the spleen. In brief, splenocytes were stimulated for 6 h with 10 μg ml −1 of OVA 257-264 peptide (SIINFEKL, Genemed Synthesis) and, during the last hour, the protein transport inhibitor monensin. Splenocytes were then subjected to intracellular IFN-γ staining and flow cytometry analysis. LM-OVA cells (2 × 10 4 CFU) were used to infect WT OT-I and Otub1-TKO OT-I mice. Seven days after infection, splenocytes were collected and stimulated for 6 h with OVA 257-264 peptide (10 μg ml + T cell and NK cell-depletion experiments, age-and sex-matched WT and Otub1-iKO mice were inoculated subcutaneously with 2 × 10 5 B16F10 melanoma cells and also injected intraperitoneally with anti-CD8 (clone YTS169.4) and anti-NK1.1 (clone PK136) neutralizing antibodies (100 μg) as depicted in Supplementary Fig. 6d .
Adoptive cell therapy was performed using Pmel1 CD8 + T cells recognizing the B16 melanoma antigen gp100. In brief, splenocytes were isolated from WT Pmel1 or Otub1-TKO Pmel1 mice and stimulated in vitro using plate-coated anti-CD3 (1 μg ml
) and soluble anti-CD28 (1 μg ml
−1
). The culture was provided with mIL-2 (10 ng ml −1 ) on day 2 and CD8 + T cells were purified from the culture on day 5 and used for adoptive transfer experiments. To generate tumor-bearing mice, WT B6 mice were injected subcutaneously with B16F10 melanoma cells. After 4 d, the tumor-bearing mice were subjected to whole-body irradiation (500 rad, 137 Cs irradiator) to induce lymphodepletion. One day after the irradiation, the mice were injected with in vitro-activated WT Pmel1 or Otub1-TKO Pmel1 CD8 + T cells (6 × 10 5 ). Control mice were not irradiated or injected with Pmel1 T cells. Tumor size was measured every other day for the indicated time period.
Mixed-bone marrow and mixed-T cell adoptive transfer. Bone marrow cells (2 × 10 6 ) isolated from Otub1-TKO (CD45.2 + ) mice were mixed with bone marrow cells from WT B6.SJL (CD45.1 + ) mice in a 1:1 ratio and adoptively transferred into irradiated (1,000 rad) Rag1 knockout mice. After 6 weeks, the bone marrowchimeric mice were killed to allow analysis of the homeostasis of T cells derived from WT (B6.SJL) and Otub1-TKO bone marrows by flow cytometry on the basis of the CD45.1 and CD45.2 congenic markers.
For mixed-T cell transfer, WT (CD45. Cs irradiator) to examine the role of IL-15 in mediating lymphopenic proliferation of CD8 + T cells.
Metabolic assays. OCR and ECAR were measured with an XF96 extracellular flux analyzer (Seahorse Bioscience) following the manufacturer's instructions. In brief, WT or Otub1-TKO CD8 + naive T cells, either freshly isolated or in vitro-activated with anti-CD3 and anti-CD28 (for 24 h), were seeded in XF96 microplates (150,000 cells per well). The plates were quickly centrifuged to immobilize the cells. After incubation in a non-buffered assay medium (Seahorse Biosciences) in an incubator without CO 2 for 30 min, the cells were subjected to glycolysis assays with an XF glycolysis stress test kit (Seahorse Biosciences). Initial measurement of ECAR was done when cells were incubated in a glycolysis stress test medium without glucose to record the baseline. Glucose (10 mM) was then injected to induce ECAR, reflecting glycolysis rate under basal conditions. Subsequently, oligomycin (1 μM) was injected to inhibit mitochondrial ATP production and shift the energy production to glycolysis, thereby measuring the maximum glycolytic capacity (also called stressed ECAR). Finally, a glucose analog, 2-deoxyglucose (100 mM), was injected to inhibit glycolysis through targeting glucose hexokinase, resulting in decreased ECAR that served as a measure to confirm the glycolysis dependence of the detected ECAR. Inhibitor studies were carried out by culturing the cells in 24-well plates (4 × 10 6 cells per well) in the presence of indicated concentrations of AKT1/2 inhibitor or DMSO.
The Mito stress test kit (Seahorse Biosciences) was used to measure OCR under different conditions. After initial measurement of baseline OCR, 1 μM oligomycin was injected to calculate ATP-linked respiration, followed by injection of the protonophore carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP; 0.25 μM) that uncouples oxygen consumption from ATP production to obtain maximal OCR (also called stressed OCR). Lastly, 0.5 μM rotenone/antimycin A was injected to inhibit complexes I and III and shut down electron transfer chain respiration for measuring non-mitochondrial respiration.
T cell and NK cell purification and in vitro treatments. CD8
+ and CD4 + T cells were isolated from splenocytes with anti-CD8-or anti-CD4-conjugated magnetic beads (Miltenyi), and naive CD8 + or CD4 + T cells were further purified by FACS sorting to ontain the CD44 lo CD62L
hi population. The naive T cells were stimulated in replicate wells of 96-well plates (2 × 10 5 cells per well) for 66 h and the culture supernatants were analyzed by ELISA (eBioscience).
NK cells were isolated from splenocytes with an NK cell isolation kit (Miltenyi). Purified NK cells were stimulated with IL-2 (5 ng ml 
RNA sequencing analysis. Naive CD8
+ T cells were isolated from the spleen of young (6-to 8-week-old) WT OT-I and Otub1-TKO OT-I mice and were either immediately lysed for RNA preparation or activated for 24 h with anti-CD3 (1 μg ml
) and anti-CD28 (1 μg ml
−1
). Total RNA was isolated with TRIzol (Invitrogen) and subjected to RNA sequencing analysis using an Illumina sequencer in the sequencing and microarray facility of the University of Texas MD Anderson Cancer Center. The raw reads were aligned to the mm10 reference genome (build mm10), using Tophat2 RNA-seq alignment software. The mapping rate was 70% overall across all the samples in the dataset. HTseq-Count was used to quantify the gene expression counts from Tophat2 alignment files. Differential expression analysis was performed on the count data using R package DESeq2. P values obtained from multiple binomial tests were adjusted using the false discovery rate (Benjamini-Hochberg). Significant genes are defined by a Benjamini-Hochberg-corrected P value cutoff of 0.05 and fold change of at least two. RNA sequencing data were analyzed by Genesis (http://genome.tugraz.at/) and multiplot (https://genepattern.broadinstitute.org/gp/pages/login.jsf). RNA sequencing data were deposited to the Gene Expression Omnibus with the accession code GSE126777.
Quantitative PCR. RNA was extracted with TRIzol reagent from isolated WT OT-I or Otub1-TKO OT-I CD8 + T cells. The RNA samples were subjected to quantitative PCR analyses using SYBR reagent (Bio-Rad). The expression of individual genes was calculated by a standard-curve method and was normalized to the expression of Actb. Gene-specific primer sets used in this study (all for mouse genes) are listed in Supplementary Table 1 .
Retroviral and lentiviral infections. Retroviral particles were prepared using the indicated expression vectors, which are based on pMIGR1-GFP or pPRIChpaHA-mCherry, as previously described 50 . For production of lentiviral particles, HEK293T cells were transfected (using the calcium method) with pGIPZ lentiviral vectors encoding OTUB1-specific shRNAs or a non-silencing control shRNA along with the packaging vectors psPAX2 and pMD2. T cells (15R-KIT) were infected with the recombinant retroviruses or lentiviruses. After 48 h, the transduced cells were enriched by flow cytometry cell sorting on the basis of GFP expression. For primary T cell infection, naive OT-I CD8 + T cells were stimulated in 12-well plates for 24 h with plate-bound anti-CD3 (1 µg ml −1 ) plus anti-CD28 (1 µg ml
) in the presence of 10 ng ml −1 IL-15 and 5 ng ml −1 IL-2 and then infected twice (at 48 h and 72 h) with retroviruses. Twenty-four hours after the second retroviral transduction, the infected T cells were starved in low-serum (0.5% FBS) medium overnight and then stimulated with IL-15 (60 ng ml ) for the indicated time periods and lysed in a kinase cell lysis buffer supplemented with phosphatase inhibitors 52 . T cell stimulation with agonistic antibodies to TCR and CD28 was performed using a crosslinking method 52 . In brief, the cells were incubated on ice with anti-CD3 (2 μg ml −1 ) and anti-CD28 (2 μg ml −1
), followed by crosslinking with goat antihamster immunoglobulin (25 μg ml −1 ) for different time periods at 37 °C and then immediately lysed as described above for immunoblot assays.
Co-immunoprecipitations were performed essentially as described 53 . Primary OT-I CD8 + T cells or cells from the 15R-KIT T cell line were stimulated with IL-15 (80 ng ml −1 ) for the indicated time periods and lysed in a kinase cell lysis buffer 52 . Cell lysates were immediately subjected to immunoprecipitation using the indicated antibodies followed by immunoblot analysis of the precipitated proteins. For ubiquitination assays, stimulated T cells or transiently transfected HEK293T cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% (vol/vol) Nonidet P-40, 0.5% (vol/vol) sodium deoxycholate and 1 mM EDTA) supplemented with 6 M urea and 4 mM N-ethylmaleimide. Lysates were diluted once with RIPA buffer and then subjected to AKT immunoprecipitation, followed by detection of ubiquitinated AKT by immunoblot. Full scans of blots for the gel figures are provided in Supplementary Figs. 9-12 + T cells were isolated on day 4 for preparation of membrane and cytosol protein fractions. In some experiments, a T cell adoptive transfer approach was used. In brief, OT-I CD8 + T cells were labeled with CFSE and adoptively transferred into Il15ra +/+ or Il15ra −/− recipient mice. After 7 d, the OT-I CD8 + T cells were isolated from recipient mice for membrane and cytosol protein preparation.
Immune signature and survival analysis of human cancer. To correlate the expression level of OTUB1 with the level of CD8
+ effector T cells in human cancer, we collected ten well-defined CD8 + T cell-associated genes to form the immune signature. We downloaded skin cutaneous melanoma tumor samples (n = 458), including clinical and mRNA expression information, from http://www.oncolnc. org/ and submitted the compiled dataset to GenePattern (https://genepattern. broadinstitute.org/gp/pages/login.jsf) to perform unsupervised hierarchicalclustering analysis. Survival data from different clusters were used for KaplanMeier estimation in GraphPad Prism software.
Statistical analysis.
For tumor clinical scores, differences between groups were evaluated by two-way ANOVA with Bonferroni correction. For survival, differences between groups were evaluated by log-rank test. Other statistical analyses were performed by two-tailed unpaired t test using GraphPad Prism software. P values less than 0.05 were considered significant and the level of significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
In our animal studies, three to four mice were required for each group on the basis of our calculation to achieve a 2.3-fold change (effect size) in a two-tailed t test with 90% power and a significance level of 5%. All statistical tests were justified as appropriate and the data met the assumptions of the tests. The variance was similar between the groups being statistically compared.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
RNA sequencing datasets were deposited to Gene Expression Omnibus with the accession code GSE126777. Other datasets generated during the current study are available from the corresponding author upon reasonable request. The human skin cutaneous melanoma datasets reported by other studies were downloaded from http://www.oncolnc.org/.
